Q-omics provides the consensus-scored IL1RAP profile across patient tissues and cancer cell-line models. IL1RAP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IL1RAP is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, IL1RAP RNA expression shows 19,527 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, THCA, and THYM as cancer lineages where IL1RAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL1RAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL1RAP survival associations across molecular data types. IL1RAP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL1RAP RNA expression–survival associations across cancer types. High IL1RAP expression shows unfavorable associations in KIRP, STAD, PAAD, LGG, BLCA and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IL1RAP RNA expression.
This table summarizes IL1RAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IL1RAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL1RAP shows lower tumor expression in LIHC and higher tumor expression in THCA, KIRC, HNSC, COAD and BLCA. The THCA box plot shows higher IL1RAP RNA expression in tumor versus normal tissue (log2 FC = +1.858, t-test p < 0.001).
This table shows molecular features associated with IL1RAP in patient tissues and cancer cell lines. In patient samples, IL1RAP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL1RAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
